Bioavailability of MTX

At higher doses, decreased bioavailability may be even more pronounced. Thus, patients may appear to respond better to parenteral therapy, when the actual explanation is that more drug is reaching the circulation. As the variation in the confidence intervals for the drop-off in f extend to 27 percent, selected patients may have an even greater difference in f between parenteral and oral dosing. Since f may drop off by a mean of 13.5 percent as the dose of MTX is increased from a starting dose of 7.5 mg to the typical maintenance weekly doses employed in RA , a patient may do better clinically when switched from oral to intramuscular or subcutaneous administration of the same dose of the drug. Bioavailability is defined as the ratio of oral drug absorption divided by intravenous drug absorption. Oral MTX is variably absorbed in the dosage range used to treat RA.

Methotrexate therapy in rheumatoid arthritis

Molecular therapeutics: Methotrexate and its mechanism of action. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. The effect of food on methotrexate absorption. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis.

Methotrexate therapy in rheumatoid arthritis: 15 years experience. Methotrexate: A perspective of its use in the treatment of rheumatic diseases. Effect of aminopterin in rheumatoid arthritis and psoriasis. Therapeutic suppression of tissue reactivity. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. To continue reading this article you need to subscribe. Thus, any impairment of glomerular filtration rate will result in sustained serum levels of the drug that may induce bone marrow or other toxicities. MTX is primarily cleared via the kidneys, with 80 to 90 percent being excreted unchanged in the urine. This was illustrated in a pharmacokinetic analysis of 15 patients taking more than 25 mg/week of MTX ; the ratio of oral to subcutaneous absorption was decreased by approximately one-third.

In vitro effects of methotrexate

The in vitro effects of methotrexate on peripheral blood mononuclear cells: Modulation by methyl donors and spermidae. Studies in healthy volunteers and patients with rheumatoid arthritis. Inhibition of cytokine production by methotrexate. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis.

Efficacy of low-dose methotrexate

Efficacy of low-dose methotrexate in rheumatoid arthritis. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment. Methotrexate remains the anchor drug for rheumatoid arthritis. Xenobiotics or biological response modifiers. Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells.

Methotrexate treatment rheumatoid arthritis

Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Comparison of two schedules for administering oral low-dose methotrexate in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study. Every-other week methotrexate in patients with rheumatoid arthritis: A double-blind, placebo-controlled prospective study. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Longterm treatment of destructive rheumatoid arthritis with methotrexate. Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. Radiologic progression in early rheumatoid arthritis treated with methotrexate. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Follow-up after a mean of 13.3 years.